Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...

Critical Care

Volumn 14, Issue 4, 2010, Pages

  Shankar Hari, Manu ^a   Wyncoll, Duncan ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; PLACEBO; PROTEIN C; DROTRECOGIN; RECOMBINANT PROTEIN;

ACUTE PANCREATITIS; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; MEDICAL LITERATURE; MORTALITY; MULTIPLE ORGAN FAILURE; NOTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; SEPSIS; PANCREATITIS; PATHOPHYSIOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; MULTIPLE ORGAN FAILURE; PANCREATITIS; PROTEIN C; RECOMBINANT PROTEINS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 78649364047     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9190     Document Type: Note

References (11)

1. Pettila V, Kyhala L, Kylanpaa M-J, Leppaniemi A, Tallgran M, Markkola A, Puolakkainen P, Kemppainen E. APCAP - activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care 2010, 14:R139. 10.1186/cc9203, 20663207.
2. Radenkovic D, Bajec D, Karamarkovic A, Stefanovic B, Milic N, Ignjatovic S, Gregoric P, Milicevic M. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 2004, 29:152-156. 10.1097/00006676-200408000-00010, 15257107.
3. Ping C, Youngping Z, Minmin Q, Weiyan Y, Yaozong Y. Activated protein C improves severity of acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin. Dig Dis Sci 2010, 55:1599-1609. 10.1007/s10620-009-0909-y, 19680809.
4. Alfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, Fernandez-del Castillo C. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006, 141:670-676. 10.1001/archsurg.141.7.670, 16847238.
5. Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand J-A, Skerett SJ, Stapleton RD, Ware LB, Waldmann CS. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004, 32:2524-2536. 10.1097/01.CCM.0000148222.09869.92, 15599161.
6. Khan A, Agarwal R, Aggarwal AN, Gupta D. Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis. Respir Care 2010, 55:901-910.
7. Camporota L, Wyncoll DLA. Practical aspects of treatment with drotrecogin alfa (activated). Crit Care 2007, 11:S7. 2230611, 18269694, 10.1186/cc6158.
8. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL, . Xigris and prophylactic heparin Evaluation in Severe Sepsis (XPRESS) Study Group Prophylactic heparin in patients with severe sepsis treated with drotrecoginalfa (activated). Am J Respir Crit Care Med 2007, 176:483-490. 10.1164/rccm.200612-1803OC, 17556722, Xigris and prophylactic heparin Evaluation in Severe Sepsis (XPRESS) Study Group.
9. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Gardlund B, Marshal JC, Rhodes A. Design, conduct, analysis and reporting of a multi-national, placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34:1935-1947. 10.1007/s00134-008-1266-6, 18839141.
10. Shorr AF, Nelson DR, Wyncoll DLA, Reinhart K, Brunkhorst F, Vail GM, Janes J. Protein C: a potential biomarker in severe sepsis an a possible tool for monitoring treatment with drotrecogin alfa (activated). Crit Care 2008, 12:R45. 2447591, 18394162, 10.1186/cc6854.
11. Ottesen LH, Bladbjerg EM, Osman M, Lausten SB, Jacobsen NO, Gran J, Jensen SL. Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg 1999, 16:486-495. 10.1159/000018774, 10805548.